A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Clinical trial NCT01887886 · COMPLETED
Trial details
- NCT number
- NCT01887886
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-01
- Primary completion
- 2015-02-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.